TY - JOUR
T1 - A global live cell barcoding approach for multiplexed mass cytometry profiling of mouse tumors
AU - Charmsaz, Soren
AU - Gross, Nicole
AU - Jaffee, Elizabeth
AU - Ho, Won Jin
N1 - Funding Information:
Funding was provided by Emerson Collective Cancer Research Fund (640183).
Funding Information:
coinventorship of patents with potential for receiving royalties from Rodeo Therapeutics (patent nos. US20180064694A1, US20200061073A1, and US20200030348A1), receiving research grant from Sanofi, and consulting for Exelixis. EMJ reports receiving a commercial research grant from Bristol-Myers Squibb, Aduro Biotech, and Amgen; having ownership interest (e.g., stock, patents) in Aduro Biotech; and being a consultant/advisory board member for CStone, Dragonfly, Genocea, and Adaptive Biotechnologies.
Publisher Copyright:
© 2021, Charmsaz et al.
PY - 2021/4/8
Y1 - 2021/4/8
N2 - With the advent of cancer immunology, mass cytometry has been increasingly employed to characterize the responses to cancer therapies and the tumor microenvironment (TME). One of its most notable applications is efficient multiplexing of samples into batches by dedicating a number of metal isotope channels to barcodes, enabling robust data acquisition and analysis. Barcoding is most effective when markers are present in all cells of interest. While CD45 has been shown to be a reliable marker for barcoding all immune cells in a given sample, a strategy to reliably barcode mouse cancer cells has not been demonstrated. To this end, we identified CD29 and CD98 as markers widely expressed by commonly used mouse cancer cell lines. We conjugated anti- CD29 and anti-CD98 antibodies to cadmium or indium metals and validated their utility in 10-plex barcoding of live cells. Finally, we established a potentially novel barcoding system incorporating the combination of CD29, CD98, and CD45 to multiplex 10 tumors from s.c. MC38 and KPC tumor models, while successfully recapitulating the known contrast in the PD1-PDL1 axis between the 2 models. The ability to barcode tumor cells along with immune cells empowers the interrogation of the tumor-immune interactions in mouse TME studies.
AB - With the advent of cancer immunology, mass cytometry has been increasingly employed to characterize the responses to cancer therapies and the tumor microenvironment (TME). One of its most notable applications is efficient multiplexing of samples into batches by dedicating a number of metal isotope channels to barcodes, enabling robust data acquisition and analysis. Barcoding is most effective when markers are present in all cells of interest. While CD45 has been shown to be a reliable marker for barcoding all immune cells in a given sample, a strategy to reliably barcode mouse cancer cells has not been demonstrated. To this end, we identified CD29 and CD98 as markers widely expressed by commonly used mouse cancer cell lines. We conjugated anti- CD29 and anti-CD98 antibodies to cadmium or indium metals and validated their utility in 10-plex barcoding of live cells. Finally, we established a potentially novel barcoding system incorporating the combination of CD29, CD98, and CD45 to multiplex 10 tumors from s.c. MC38 and KPC tumor models, while successfully recapitulating the known contrast in the PD1-PDL1 axis between the 2 models. The ability to barcode tumor cells along with immune cells empowers the interrogation of the tumor-immune interactions in mouse TME studies.
UR - http://www.scopus.com/inward/record.url?scp=85104160032&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104160032&partnerID=8YFLogxK
U2 - 10.1172/jci.insight.143283
DO - 10.1172/jci.insight.143283
M3 - Article
C2 - 33690223
AN - SCOPUS:85104160032
SN - 2379-3708
VL - 6
JO - JCI Insight
JF - JCI Insight
IS - 7
M1 - e143283
ER -